Created at	Source	Raw Value	Validated value
Dec. 1, 2021, 11 p.m.	usa	Adverse events (AEs);Neutralizing antibody against SARS-CoV-2 wild type and variants of concern (VOCs);Neutralizing antibody against SARS-CoV-2 wild type and variants of concern (VOCs);SRAS-CoV-2 S protein-binding antibodies;SRAS-CoV-2 S protein-binding antibodies	Adverse events (AEs);Neutralizing antibody against SARS-CoV-2 wild type and variants of concern (VOCs);Neutralizing antibody against SARS-CoV-2 wild type and variants of concern (VOCs);SRAS-CoV-2 S protein-binding antibodies;SRAS-CoV-2 S protein-binding antibodies